77 related articles for article (PubMed ID: 1305679)
1. 13-cis-retinoic acid in chemoprevention of superficial bladder cancer. The National Bladder Cancer Group.
Prout GR; Barton BA
J Cell Biochem Suppl; 1992; 16I():148-52. PubMed ID: 1305679
[TBL] [Abstract][Full Text] [Related]
2. The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years.
Holmäng S; Hedelin H; Anderström C; Johansson SL
J Urol; 1995 Jun; 153(6):1823-6; discussion 1826-7. PubMed ID: 7752327
[TBL] [Abstract][Full Text] [Related]
3. A randomized controlled trial of short-term versus long-term prophylactic intravesical instillation chemotherapy for recurrence after transurethral resection of Ta/T1 transitional cell carcinoma of the bladder.
Koga H; Kuroiwa K; Yamaguchi A; Osada Y; Tsuneyoshi M; Naito S
J Urol; 2004 Jan; 171(1):153-7. PubMed ID: 14665865
[TBL] [Abstract][Full Text] [Related]
4. Superficial transitional cell carcinoma of the ureteral orifice: higher risk of developing subsequent upper urinary tract tumors.
Chou EC; Lin AT; Chen KK; Chang LS
Int J Urol; 2006 Jun; 13(6):682-5. PubMed ID: 16834642
[TBL] [Abstract][Full Text] [Related]
5. [Clinical research on prevention of recurrence of superficial bladder cancer--comparative study on clinical efficacy of bleomycin intravesical instillation and bestatin].
Kumamoto Y; Tsukamoto T; Tamiya T; Takatsuka K; Furuya S; Yokoyama E; Honma A; Aoyama T; Tanda H; Kato S
Hinyokika Kiyo; 1985 Oct; 31(10):1861-83. PubMed ID: 2418659
[TBL] [Abstract][Full Text] [Related]
6. [Microdoses of BCG vaccine for prophylaxis in bladder cancer stage T1].
Rivera P; Caffarena E; Cornejo H; Del Pino M; Fonerón A; Haemmersli J; Sepúlveda M; Ubilla A
Actas Urol Esp; 1993 Apr; 17(4):243-6. PubMed ID: 8342414
[TBL] [Abstract][Full Text] [Related]
7. Fluid intake and the risk of tumor recurrence in patients with superficial bladder cancer.
Donat SM; Bayuga S; Herr HW; Berwick M
J Urol; 2003 Nov; 170(5):1777-80. PubMed ID: 14532774
[TBL] [Abstract][Full Text] [Related]
8. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer.
Librenjak D; Situm M; Eterovic D; Dogas Z; Gotovac J
Croat Med J; 2003 Apr; 44(2):187-92. PubMed ID: 12698510
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors for primary superficial transitional cell carcinoma of the bladder: a retrospective cohort study.
Yang TB; Zeng FH; Sun ZQ
Chin Med J (Engl); 2006 Nov; 119(21):1821-8. PubMed ID: 17097038
[TBL] [Abstract][Full Text] [Related]
10. The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour.
Solsona E; Iborra I; Rubio J; Casanova J; Almenar S
BJU Int; 2004 Dec; 94(9):1258-62. PubMed ID: 15610101
[TBL] [Abstract][Full Text] [Related]
11. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for upper tract recurrence in patients undergoing long-term surveillance for stage ta bladder cancer.
Canales BK; Anderson JK; Premoli J; Slaton JW
J Urol; 2006 Jan; 175(1):74-7. PubMed ID: 16406874
[TBL] [Abstract][Full Text] [Related]
13. Pathologic features of bladder tumors after nephroureterectomy or segmental ureterectomy for upper urinary tract transitional cell carcinoma.
Raman JD; Sosa RE; Vaughan ED; Scherr DS
Urology; 2007 Feb; 69(2):251-4. PubMed ID: 17320658
[TBL] [Abstract][Full Text] [Related]
14. Surgically treated transitional cell carcinomas of the bladder. The role of radical surgery.
Al-Ali MA; Kashmoula DM; Haddad LF
Saudi Med J; 2002 Jun; 23(6):695-9. PubMed ID: 12070550
[TBL] [Abstract][Full Text] [Related]
15. Randomized prospective phase III trial of difluoromethylornithine vs placebo in preventing recurrence of completely resected low risk superficial bladder cancer.
Messing E; Kim KM; Sharkey F; Schultz M; Parnes H; Kim D; Saltzstein D; Wilding G
J Urol; 2006 Aug; 176(2):500-4. PubMed ID: 16813878
[TBL] [Abstract][Full Text] [Related]
16. Twelve-year follow up of a randomized prospective trial comparing bacillus Calmette-Guerin and epirubicin as adjuvant therapy in superficial bladder cancer.
Cheng CW; Chan SF; Chan LW; Chan CK; Ng CF; Cheung HY; Chan SY; Wong WS; Lai FM; To KF; Li ML
Int J Urol; 2005 May; 12(5):449-55. PubMed ID: 15948743
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in voided urine samples from patients with transitional cell carcinoma of the bladder.
Durkan GC; Nutt JE; Rajjayabun PH; Neal DE; Lunec J; Mellon JK
Clin Cancer Res; 2001 Nov; 7(11):3450-6. PubMed ID: 11705862
[TBL] [Abstract][Full Text] [Related]
18. Clinical panurothelial disease in patients with superficial bladder tumors: therapeutic implications.
Solsona E; Iborra I; Ricos JV; Monros JL; Rubio J; Almenar S
J Urol; 2002 May; 167(5):2007-11. PubMed ID: 11956428
[TBL] [Abstract][Full Text] [Related]
19. Results of the phase II EORTC 22971 trial evaluating combined accelerated external radiation and chemotherapy with 5FU and cisplatin in patients with muscle invasive transitional cell carcinoma of the bladder.
Poortmans PM; Richaud P; Collette L; Ho Goey S; Pierart M; Van Der Hulst M; Bolla M;
Acta Oncol; 2008; 47(5):937-40. PubMed ID: 18568488
[TBL] [Abstract][Full Text] [Related]
20. [The sensitivity and clinical implications of periodical bladder biopsy following transurethral resection of superficial bladder transitional cell carcinoma].
Kanematsu A; Tsuji Y; Kanba H; Noguchi T; Kamoto T; Okabe T
Hinyokika Kiyo; 2001 Jan; 47(1):1-4. PubMed ID: 11235213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
